| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC1508 |
| Trial ID | NCT02348216 |
| Disease | High-Grade B-Cell Lymphoma | Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Primary Mediastinal B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | YesCAR-Ta|Axicabtagene Ciloleucel|axi-cel |
| Generation | 2nd |
| Phase | Phase1|Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma |
| Year | 2015 |
| Country | United States |
| Company sponsor | Kite, A Gilead Company |
| Other ID(s) | KTE-C19-101|2015-005007-86 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||||
|
|||||||||||||